Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Everest Medicines Ltd. ( (HK:1952) ) has issued an announcement.
Everest Medicines has scheduled a board meeting for 25 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025. The meeting will also address any other board business, signaling the start of the company’s formal reporting cycle for 2025 and providing an upcoming disclosure event that will be closely watched by investors for insights into financial performance and strategic direction.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$36.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Limited is a biopharmaceutical company listed on the Hong Kong Stock Exchange, focusing on developing and commercializing innovative medicines. The group operates through a board structure comprising executive, non-executive, and independent non-executive directors, reflecting a typical governance framework for Hong Kong–listed life sciences firms.
Average Trading Volume: 3,522,870
Technical Sentiment Signal: Sell
Current Market Cap: HK$12.59B
Learn more about 1952 stock on TipRanks’ Stock Analysis page.